




Effects of intranasal oxytocin on cocaine-conditioned locomotion and anxiety-like behaviors in rats.

Mentor: Carmen S. Maldonado-Vlaar, PhD

Amanda V. Marti Mendoza
NeuroID Research Program



ADDICTION

- Addiction is a chronic disease characterized by compulsive, or uncontrollable, drug seeking and use despite harmful consequences and changes in the brain, which can be long lasting.
- Psychostimulants have a sympathomimetic effect as the result of the activation of the Sympathetic Nervous System (“Fight or flight”).
- Mesolimbic Pathway (Dopaminergic) – Reward Pathway
 - Ventral Tegmental Area (VTA)
 - Nucleus Accumbens
 - Prefrontal Cortex



COCAINE

- Is a psychostimulant that produces changes in brain regions implicated in drug reward.
- Has specific cellular actions within the Nucleus Accumbens – Potentiates pleasure
- Acts as inhibitor of the dopamine transporter, therefore inhibiting this neurotransmitter's reuptake.
- Produces behavioral sensitization



OBJECTIVE

To examine the effects of intranasal administration of oxytocin on cocaine-conditioned locomotion and anxiety-like response in male rats.


HYPOTHESIS

Intranasal infusions of oxytocin will reduce cocaine-conditioned locomotion and anxiety-like behaviors in male rats.

METHODS

Intraperitoneal Injections

- 20 Sprague Dawley male rats were injected intraperitoneally with Saline 0.9% (Control) or Cocaine 10 mg/kg (Experimental).




Cocaine Conditioning for 5 days

- Rats were exposed to activity chambers with olfactory (orange) and visual (black box) cues for 90 minutes.


Day 7 Test Day

- Rats were exposed to activity chambers 30 minutes after intranasal infusions of oxytocin (1 $\mu\text{g}/\mu\text{L}$) with olfactory (orange) and visual (black box) cues **ONLY** for 60 minutes. Rats were then exposed to Elevated Plus Maze.

TEST DAY EXPERIMENTAL DESIGN




Min -30 ----- 0 ----- 60 ----- 65 -----



RESULTS - CONDITIONING

Total Movement (90 mins)



Total Movement Time (90 mins)




Figure 1: Experimental group moved more than controls in total movement (TM) from Day 1 to Day 5.

Figure 2: Experimental group spent more time moving than controls in total movement time (TMT) from Day 1 to Day 5

RESULTS - CONDITIONING





Figure 3: Ambulatory distance (AD) increased from Day 1 to Day 5 in experimental animals when compared to controls.

RESULTS – TEST DAY (CUES ONLY)

Total Movement Time (60 mins)



Total Movement (60 mins)




Figure 4: Experimental group treated with OT moved for a longer time (TMT) than those treated with Vehicle

Figure 5: Experimental group treated with OT moved more (TM) than those treated with Vehicle

RESULTS – TEST DAY (CUES ONLY)





Figure 6: Experimental group treated with OT showed more ambulatory distance (AD) than the one with Vehicle treatment

RESULTS – TEST DAY

Open Arms



Closed Arms




Figure 7: Experimental group treated with OT spent more time in the Open Arms of the EPM than the group with Vehicle treatment

Figure 8: Experimental group treated with OT spent less time in the Closed Arms of the EPM than the group with Vehicle treatment

DISCUSSION

Experimental animals showed a trend of enhancement of cocaine-conditioning when exposed to only cocaine-paired cues.

Intranasal OT showed an enhancement of cocaine-conditioned locomotion.

Intranasal OT showed an anxiolytic effect in cocaine-conditioned male rats exposed to EPM.

CONCLUSIONS

Intranasal OT attenuates anxiety-like response triggered by cocaine-paired cues in male rats.

Intranasal OT could have anxiolytic effects in drug seeking behaviors in a dose-dependent manner.

Our results suggest a therapeutical potential of OT treatment in cocaine-addiction.

REFERENCES

- Breedlove, S., Watson, N. (2013). *Biological Psychology: an introduction to behavioral, cognitive, and clinical neuroscience*. Sunderland, MA: Sinauer Associates, Inc.
- Cardoso, C., Ellenbogen, M.A., Orlando, M.A., Bacon, S.L., Joober, R. (2013) Intranasal oxytocin attenuates the cortisol response to physical stress: A dose-response study. *Psychoneuroendocrinology*, 38, (3) 399-407. doi: <http://dx.doi.org/10.1016/j.psyneuen.2012.07.013>
- Kovács, G.L., Sarnyai, Z., Szabó, G. (1998) Oxytocin and addiction: A review. *Psychoneuroendocrinology*, 23, (8) 945-962. doi: [http://dx.doi.org/10.1016/S0306-4530\(98\)00064-X](http://dx.doi.org/10.1016/S0306-4530(98)00064-X)
- Lukas, M., Neumann, I.D., (2012) Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: Social versus non-social effects. *Neuropharmacology*, 62, 398-405. doi: [10.1016/j.neuropharm.2011.08.016](https://doi.org/10.1016/j.neuropharm.2011.08.016)
- Morales-Rivera, A., Hernández-Burgos, M.M., Martínez-Rivera, A., Pérez-Colón, J., Rivera, R., Montalvo, J., Rodríguez-Borrero, E., Maldonado-Vlaar, C.S. (2014) Anxiolytic effects of oxytocin in cue-induced cocaine seeking behavior in rats. *Psychopharmacology*, 231, (21) 4145-4155. doi: [10.1007/s00213-014-3553-y](https://doi.org/10.1007/s00213-014-3553-y)
- Neumann, I.D., Landgraf, R. (2012) Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. *Trends in neurosciences*, 35, (11) 649-659. doi: <http://dx.doi.org/10.1016/j.tins.2012.08.004>
- Neumann, I.D., Maloumy, R., Beiderbeck, M.L., Landgraf, R. (2013) Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. *Psychoneuroendocrinology*, 38, (10) 1985-1993. doi: <http://dx.doi.org/10.1016/j.psyneuen.2013.03.003>
- Smith, A.S., Tabbac, M., Lei, K., Eastham, P., Btler, M.J., Linton, L., Altshuler, R., Liu, Y., Wang, Z. (2016) Local oxytocin tempers anxiety by activating GABAA receptors in the hypothalamic paraventricular nucleus. *Psychoneuroendocrinology*, 63, 50-58. doi: <http://dx.doi.org/10.1016/j.psyneuen.2015.09.017>
- Treatment Approaches for Drug Addiction. (n.d.). Retrieved July 31, 2016, from <https://www.drugabuse.gov/publications/drugfacts/treatment-approaches-drug-addiction>

ACKNOWLEDGEMENTS

- NeuroID Research Program
- University of Puerto Rico, Río Piedras Campus
- National Institutes of Health
- Carmen S. Maldonado-Vlaar, PhD - Mentor, NeuroID Co-Director
- José E. García-Arrarás, PhD - NeuroID Director
- Almaris Figueroa, Andrea López, Alejandro Loyola, Edgardo Torres, Gian C. Molina, Javier Soliván – Undergraduate Students
- Sergio Serrano, Wickensonn Norze – Graduate Students



National Institutes
of Health